methylformamide has been researched along with Ovarian Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chubb, D; Gate, EN; Gescher, A; Hickman, JA; Langdon, SP; Stevens, MF; Threadgill, MD; Vickers, LM | 1 |
| Atassi, G; Gescher, A; Gibson, NW; Hickman, JA; Langdon, SP; Ross, D | 1 |
| Berek, JS; Blessing, JA; McGuire, WP; Munoz, A | 1 |
3 other study(ies) available for methylformamide and Ovarian Neoplasms
| Article | Year |
|---|---|
Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.
Topics: Animals; Antineoplastic Agents; Female; Formamides; Hydroxylation; Lymphoma; Magnetic Resonance Spectroscopy; Mice; Ovarian Neoplasms; Structure-Activity Relationship | 1986 |
N-methylformamide: antitumour activity and metabolism in mice.
Topics: Animals; Antineoplastic Agents; Female; Formamides; Kinetics; Liver; Lymphoma; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Neoplasms, Experimental; Ovarian Neoplasms; Sarcoma, Experimental; Sulfhydryl Compounds | 1982 |
Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Drug Evaluation; Female; Formamides; Humans; Middle Aged; Ovarian Neoplasms | 1990 |